STAT3 is necessary for proliferation and survival in colon cancer-initiating cells

Cancer Research

Volumn 71, Issue 23, 2011, Pages 7226-7237

  Lin, Li ^a,d   Liu, Aiguo ^a,d   Peng, Zhengang ^c   Lin, Huey Jen ^b,c   Li, Pui Kai ^b   Li, Chenglong ^b   Lin, Jiayuh ^a,b  

^a THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c OHIO STATE UNIVERSITY   (United States)

^d HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALDEHYDE DEHYDROGENASE; CD133 ANTIGEN; DOXORUBICIN; FLUOROURACIL; INTERLEUKIN 6; LLL 12; PROTEINASE INHIBITOR; SHORT HAIRPIN RNA; STAT3 PROTEIN; STATTIC; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; CANCER INHIBITION; CELL FRACTIONATION; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; COLON CANCER; COLORECTAL CANCER; CONTROLLED STUDY; DOWNSTREAM PROCESSING; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPHOCYTE SUBPOPULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS INHIBITION; RNA INTERFERENCE; TUMOR CELL; TUMOR XENOGRAFT;

ALDEHYDE DEHYDROGENASE; ANIMALS; ANTHRAQUINONES; ANTIGENS, CD; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CELL SURVIVAL; COLONIC NEOPLASMS; CYCLIC S-OXIDES; FEMALE; GENE EXPRESSION; GENE KNOCKDOWN TECHNIQUES; GLYCOPROTEINS; HCT116 CELLS; HT29 CELLS; HUMANS; INTERLEUKIN-6; ISOENZYMES; MICE; MICE, INBRED NOD; MICE, SCID; NEOPLASTIC STEM CELLS; PEPTIDES; PHOSPHORYLATION; RETINAL DEHYDROGENASE; RNA INTERFERENCE; RNA, SMALL INTERFERING; STAT3 TRANSCRIPTION FACTOR; SULFONAMIDES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 82655189564     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-4660     Document Type: Article

References (42)

1. Ma X, Wang S, Ye Y, Du R, Cui Z, Somsouk M. Constitutive activation of Stat3 signaling pathway in human colorectal carcinoma. World J Gastroenterol 2004;10:1569-73. (Pubitemid 38786933)
2. Corvinus FM, Orth C, Moriggl R, Tsareva SA, Wagner S, Pfitzner EB, et al. Persistent STAT3 activation in colon cancer is associated with enhanced cell proliferation and tumor growth. Neoplasia 2005;7:545-55. (Pubitemid 40967755)
3. Kusaba T, Nakayama T, Yamazumi K, Yakata Y, Yoshizaki A, Nagayasu T, et al. Expression of p-STAT3 in human colorectal adenocarcinoma and adenoma; correlation with clinicopathological factors. J Clin Pathol 2005;58:833-8. (Pubitemid 41113390)
4. Lin Q, Lai R, Chirieac LR, Li C, Thomazy VA, Grammatikakis I, et al. Constitutive activation of JAK3/STAT3 in colon carcinoma tumors and cell lines: inhibition of JAK3/STAT3 signaling induces apoptosis and cell cycle arrest of colon carcinoma cells. Am J Pathol 2005;167:969-80. (Pubitemid 41416250)
5. Xiong H, Zhang Z, Tian X, Sun D, Liang Q, Zhang Y, et al. Inhibition of JAK1, 2/STAT3 signaling induces apoptosis, cell cycle arrest, and reduces tumor cell invasion in colorectal cancer cells. Neoplasia 2008;10:287-97. (Pubitemid 351328587)
6. Tsareva S, Moriggl R, Corvinus F, Wiederanders B, Schütz A, Kovacic B, et al. Signal transducer and activator of transcription 3 activation promotes invasive growth of colon carcinomas through matrix metalloproteinase induction. Neoplasia 2007;9:279-91. (Pubitemid 46608295)
7. Boman BM, Wicha MS. Cancer stem cells: a step toward the cure. J Clin Oncol 2008;26:2795-9.
8. Boman BM, Huang E. Human colon cancer stem cells: a new paradigm in gastrointestinal oncology. J Clin Oncol 2008;26:2828-38.
9. Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, Peschle C, et al. Identification and expansion of human colon-cancer-initiating cells. Nature 2007;445:111-5. (Pubitemid 46067311)
10. O'Brien CA, Pollett A, Gallinger S, Dick JE. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007;445:106-10. (Pubitemid 46067310)
11. Shmelkov SV, Butler JM, Hooper AT, Hormigo A, Kushner J, Milde T, et al. CD133 expression is not restricted to stem cells, and both CD133+ and CD133- metastatic colon cancer cells initiate tumors. J Clin Invest 2008;118:2111-20. (Pubitemid 351872330)
12. Magni M, Shammah S, Schiro R, Mellado W, Dalla-Favera R, Gianni AM. Induction of cyclophosphamide-resistance by aldehyde-dehydrogenase gene transfer. Blood 1996;87:1097-103. (Pubitemid 26043537)
13. Corti S, Locatelli F, Papadimitriou D, Donadoni C, Salani S, Del Bo R, et al. Identification of a primitive brain-derived neural stem cell population based on aldehyde dehydrogenase activity. Stem Cells 2006;24:975-85. (Pubitemid 44464730)
14. Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M, et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a opredictor of poor clinical outcome. Cell Stem Cell 2007;1:555-67. (Pubitemid 350056407)
15. Charafe-Jauffret E, Ginestier C, Iovino F, Wicinski J, Cervera N, Finetti P, et al. Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. Cancer Res 2009;69:1302-13.
16. Huang EH, Hynes MJ, Zhang T, Ginestier C, Dontu G, Appelman H, et al. Aldehyde dehydrogenase 1 is a marker for normal and malignant human colonic stem cells (SC) and tracks SC overpopulation during colon tumorigenesis. Cancer Res 2009;69:3382-9.
17. Lin L, Hutzen B, Li P, Ball S, Zuo M, DeAngelis S, et al. A novel small molecule, LLL12, inhibits STAT3 phosphorylation and activities and exhibits potent growth-suppresive activity in human cancer cells. Neoplasia 2010;12:39-50.
18. Schust J, Sperl B, Hollis A, Mayer TU, Berg T. Stattic: a small-molecule inhibitor of STAT3 activation and dimerization. Chem Biol 2006;13:1235-42. (Pubitemid 44750735)
19. Carro MS, Lim WK, Alvarez MJ, Bollo RJ, Zhao X, Snyder EY, et al. The transcriptional network for mesenchymal transformation of brain tumours. Nature 2010;463:318-25.
20. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 2003;100:3983-8. (Pubitemid 36418143)
21. Buettner R, Mora LB, Jove R. Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin Cancer Res 2002;8:945-54. (Pubitemid 35177340)
22. Turkson J, Jove R. STAT proteins: novel molecular targets for cancer drug discovery. Oncogene 2000;19:6613-26. (Pubitemid 32197700)
23. Kaptein A, Paillard V, Saunders M. Dominant negative stat3 mutant inhibits interleukin-6-induced Jak-STAT signal transduction. J Biol Chem 1996;271:5961-4. (Pubitemid 26095392)
24. Schaefer T, Sanders L, Park O, Nathans D. Functional differences between STAT 3 and STAT 3. Mol Cell Biol 1997;17:5307-16.
25. Faruqi T, Gomez D, Bustelo X, Bar-Sagi D, Reich N. Rac1 mediates STAT3 activation by autocrine IL-6. Proc Natl Acad Sci U S A 2001:9014-9. (Pubitemid 32743861)
26. Bromberg J, Wrzeszczynska M, Devgan G, Zhao Y, Pestell R, Albanese C, et al. Stat3 as an oncogene. Cell 1999;98:295-303. (Pubitemid 29380565)
27. Gritsko T, Williams A, Turkson J, Kaneko S, Bowman T, Huang M, et al. Persistent activation of stat3 signaling induces survivin gene expression and confers resistance to apoptosis in human breast cancer cells. Clin Cancer Res 2006;12:11-9. (Pubitemid 43166170)
28. Grivennikov S, Karin M. Autocrine IL-6 signaling: a key event in tumorigenesis? Cancer Cell 2008;13:7-9. (Pubitemid 350309747)
29. Studebaker AW, Storci G, Werbeck JL, Sansone P, Sasser AK, Tavolari S, et al. Fibroblasts isolated from common sites of breast cancer metastasis enhance cancer cell growth rates and invasiveness in an interleukin-6-dependent manner. Cancer Res 2008;68:9087-95.
30. Dontu G, Jackson KW, McNicholas E, Kawamura MJ, Abdallah WM, Wicha MS. Role of notch signaling in cell-fate determination of human mammary stem/progenitor cells. Breast Cancer Res 2004;6:R605-15.
31. Gough DJ, Corlett A, Schlessinger K, Wegrzyn J, Larner AC, DE L. Mitochondrial STAT3 supports Ras-dependent oncogenic transformation. Science 2009;324:1713-6.
32. Ling X, Arlinghaus RB. Knockdown of STAT3 expression by RNA interference inhibits the induction of breast tumors in immunocompetent mice. Cancer Res 2005;65:2532-6. (Pubitemid 40490046)
33. Fuh B, Sobo M, Cen L, Josiah D, Hutzen B, Cisek K, et al. LLL-3 inhibits STAT3 activity, suppresses glioblastoma cell growth and prolongs survival in a mouse glioblastoma model. Br J Cancer 2009;100:106-12.
34. Bhasin D, Cisek K, Pandharkar T, Regan N, Li C, Pandit B, et al. Design, synthesis, and studies of small molecule STAT3 inhibitors. Bioorg Med Chem Lett 2008;18:391-5.
35. Zhong Z, Wen Z, Darnell JE Jr. Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. Science 1994;264:95-8. (Pubitemid 24144493)
36. Grivennikov S, Karin E, Terzic J, Mucida D, Yu GY, Vallabhapurapu S, et al. IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell 2009;15:103-13.
37. Bollrath J, Phesse T, von Burstin V, Putoczki T, Bennecke M, Bateman T, et al. gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis. Cancer Cell 2009;15:79-80.
38. Becker C, Fantini MC, Wirtz S, Nikolaev A, Lehr HA, Galle PR, et al. IL-6 signaling promotes tumor growth in colorectal cancer. Cell Cycle 2005;4:217-20. (Pubitemid 41365319)
39. Gharavi NM, Alva JA, Mouillesseaux KP, Lai C, Yeh M, Yeung W, et al. Role of the Jak/STAT pathway in the regulation of interleukin-8 transcription by oxidized phospholipids in vitro and in atherosclerosis in vivo. J Biol Chem 2007;282:1460-8.
40. Ginestier C, Liu S, Diebel ME, Korkaya H, Luo M, Brown M, et al. CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts. J Clin Invest 2010;120:485-97.
41. Sherry MM, Reeves A, Wu JK, Cochran BH. STAT3 is required for proliferation and maintenance of multipotency in glioblastoma stem cells. Stem Cells 2009;27:2383-92.
42. Wang H, Lathia JD, Wu Q, Wang J, Li Z, Heddleston JM, et al. Targeting interleukin 6 signaling suppresses glioma stem cell survival and tumor growth. Stem Cells 2009;27:2393-404.